drugset / Trial / NCT00253474
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
Phase 1
Completed
36 enrolled
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b in treating young patients with plexiform neurofibroma.
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 1 ug/kg | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 4.5 ug/kg | Subcutaneous |